Marker Therapeutics (FRA:GX1) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Marker Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was €0.00 Mil. Marker Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was €16.98 Mil. Therefore, Marker Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Marker Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Marker Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Gross-Profit-to-Asset % Chart

Marker Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.40

0.97

Marker Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	44.63	-	-	-

Competitive Comparison of Marker Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Marker Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Gross-Profit-to-Asset % falls into.

Marker Therapeutics Gross-Profit-to-Asset % Calculation

Marker Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (32.494	+	15.705)	/ 2 )
	=	0	/	24.0995
	=	0.00 %

Marker Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (18.259	+	15.705)	/ 2 )
	=	0	/	16.982
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Marker Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (FRA:GX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics (FRA:GX1) Headlines

No Headlines